PRKN and idiopathic pulmonary fibrosis: Pirfenidone, an FDA-approved therapy and an exciting landmark in the field of IPF treatment, exerts its antifibrotic effects partially through the induction of PARK2-mediated mitophagy and the inhibition of myofibroblast differentiation [42].